GSK plc (GSK, GSK.L) announced that the FDA has approved Jemperli for use in combination with carboplatin and paclitaxel, followed by Jemperli as a monotherapy, for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This approval extends the previous indication to now include patients with mismatch repair-proficient/microsatellite stable tumors, who constitute 70-75% of those diagnosed with endometrial cancer.
Jemperli was discovered by AnaptysBio and subsequently licensed to TESARO under a collaboration and exclusive license agreement established in March 2014. GSK is currently responsible for the research, development, commercialization, and manufacturing of both Jemperli and cobolimab.
